Finally, one study  found no difference in renal function (evaluated by glomerular filtration rate using 51Cr-EDTA) between 9 patients under nucleoside and 15 under nucleotide analogues followed for a median of 24 months. Of course, longer safety data for the hgbNAs are needed in the HBV transplant setting. In conclusion, our findings favor the use of HBIG and a hgbNA instead of HBIG and LAM combined prophylaxis against HBV recurrence, as such a strategy further increases the efficacy of post-LT prophylaxis in HBV transplant patients achieving negligible rates of HBV recurrence. The use of ETV or TDF can be effectively combined with lower HBIG dosages even at the early post-LT period. Further studies are required to decide whether, when and perhaps in which subgroups HBIG can be discontinued in patients under a hgbNA. Similarly, the efficacy and effectiveness of HBIG-free prophylaxis Alisertib
based on hgbNA(s) should be evaluated initially in well-designed clinical studies and subsequently in clinical practice. None. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. ""Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD) and may present after kidney transplantation, a condition known as posttransplantation EPS. The prevalence and impact of posttransplantation EPS on survival after kidney transplantation is unknown. From January 1, 1996 until July 1, 2007, 1241 PD patients were transplanted. Thirty-eight cases of posttransplantation EPS (3%) were identified from the Dutch multicenter EPS study. In EPS patients the mean pretransplant click here
dialysis duration was longer than in the controls (71.4 �� 37.5 months vs. 34.7 �� 25.5, p < 0.0001). The majority of EPS cases were observed within the first 2 years after transplantation, but some cases appeared many years after transplantation. Two hundred and one (16.2%) patients died after transplantation, Cabozantinib research buy
of which 17 were EPS patients. After infection (23.9%), cardiovascular disease (21.9%) and malignancy (10.9%), EPS (8.5%) was the fourth known cause of death after transplantation. Kaplan�CMeier analysis showed a significant decreased survival for transplanted patients with posttransplantation EPS compared to transplanted patients without EPS. In conclusion, posttransplantation EPS is rare but carries a high mortality. A prolonged clinical vigilance and a high index of suspicion for the diagnosis are warranted, specifically in PD patients with a relatively long cumulative pretransplant duration of PD. Peritoneal dialysis (PD) is a well-established renal replacement therapy, preferred by many young patients with end-stage renal disease in good clinical condition. Most PD patients are eligible for kidney transplantation and there is no apparent difference in rate of infections or patient survival between transplanted PD and hemodialysis (HD) patients (1,2).